• Most Popular
  • Most Shared

Transgene upbeat over hepatitis C vaccine product

Mon May 19, 2008 12:11pm EDT

Stocks

   

PARIS, May 19 (Reuters) - French biotechnology company Transgene (TRNG.PA) said on Monday that its hepatitis c virus (HCV) therapeutic vaccine TG4040 product had delivered promising Phase I results.

Transgene said in a statement that a preliminary analysis showed that the product had a "favourable safety profile".

"These results, despite their preliminary and partial nature, are very encouraging and indicate that TG4040 is active against hepatitis C," said Chief Executive Philippe Archinard.

Transgene shares closed up 7 percent at 17.65 euros, giving the company a stock market value of around 390 million euros ($608.3 million).

(Reporting by Sudip Kar-Gupta, editing by Elizabeth Fullerton)



More from Reuters

Photo

Saab says bid deadline dropped

AMSTERDAM (Reuters) - General Motors has extended a December 31 deadline for bids for its Swedish car brand Saab, which will restart some production lines in January after a shutdown, Saab said on Wednesday.

» More Top News
Maria Montero carries plastic products for quality control inspection at Blow Molded Plastics in Pawtucket, Rhode Island November 17, 2009. REUTERS/Brian Snyder

Learning to survive and thrive

Small manufacturers in states like Alabama are taking a risk on innovation to compete with with low-cost competition. It's working. The second installment in a three-part report.  Full Article 

Route to Recovery
Disgraced financier Bernard Madoff is escorted by police and photographed by the media as he departs U.S. Federal Court after a hearing in New York, January 5, 2009. REUTERS/Lucas Jackson

I beg your pardon ...

Bernie Madoff became the poster boy of crooked investment schemes this year -- but he wasn't alone. Here's a look at the 10 most notorious cases of 2009.  Full Article 

Corporate Crime